The global Benign Prostatic Hyperplasia (BPH) surgical treatment market is experiencing substantial growth, driven by the increasing prevalence of BPH among aging males and the rising demand for effective surgical interventions. BPH, a non-cancerous enlargement of the prostate gland, leads to lower urinary tract symptoms (LUTS) that significantly impact the quality of life. Surgical treatments are often pursued when pharmacological therapies fail to provide adequate relief.
In 2024, the market was valued at approximately USD 12.62 billionand is projected to reach USD 21.19 billion by 2034, growing at a compound annual grow
Synes godt om
Kommentar
Del
